Journal article icon

Journal article

Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria

Abstract:
PURPOSE Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND METHODS Participating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1. RESULTS Respondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception. CONCLUSION This study investigated COVID-19–influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1200/go.21.00244

Authors

More by this author
Role:
Author
ORCID:
0000-0002-7938-1218
More by this author
Role:
Author
ORCID:
0000-0002-8295-8735
More by this author
Role:
Author
ORCID:
0000-0002-0690-8242
More by this author
Role:
Author
ORCID:
0000-0001-5208-8073
More by this author
Role:
Author
ORCID:
0000-0002-3775-0492


Publisher:
American Society of Clinical Oncology
Journal:
JCO Global Oncology More from this journal
Volume:
8
Issue:
8
Pages:
e2100244-e2100244
Publication date:
2022-02-14
DOI:
EISSN:
2687-8941
ISSN:
2687-8941


Language:
English
Keywords:
Pubs id:
2429073
Local pid:
pubs:2429073
Source identifiers:
W4213041457
Deposit date:
2026-06-04
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP